The Paradoxical Role of Body Mass Index in Patients with Muscle-invasive Bladder Cancer Receiving Neoadjuvant Immunotherapy

Eur Urol Oncol. 2022 Jun;5(3):370-372. doi: 10.1016/j.euo.2022.02.004. Epub 2022 Mar 10.
No abstract available

Publication types

  • Letter

MeSH terms

  • Body Mass Index
  • Humans
  • Immunotherapy / adverse effects
  • Muscles
  • Neoadjuvant Therapy
  • Urinary Bladder Neoplasms* / therapy

Associated data

  • ClinicalTrials.gov/NCT02736266